This dual-purpose compound plant nutrition beverage, which is the first in China and the leading in the world, has been recognized by clinical experts and is suitable for patients with hyperuricemia and gout. Is it really as effective as advertised? Is safety guaranteed?
Looking through relevant data, it is found that clinical trials have confirmed the effectiveness and safety of Qingfengkang in reducing serum uric acid.
The clinical trial on the efficacy and safety of Qingfengkang in treating primary gout with hyperuricemia was led by Professor Li Changgui, a scholar from Taishan, Shandong Province, director of the Institute of Metabolic Diseases of Qingdao University, and director of the Department of Metabolic Diseases of the Affiliated Hospital of Qingdao University.
The experimental results were presented at various academic conferences on gout and hyperuricemia.
Results: At the end of 12, the serum uric acid in the experimental group was lower than that in the control group 154.99 μ mol/L 79.78, and Qingfengkang could further reduce the serum uric acid level by 26.99μmol/L, with statistical significance (P=0.02).